Rituximab in a childhood-onset idiopathic refractory chronic inflammatory demyelinating polyneuropathy

Abstract Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of paediatric neurology Vol. 16; no. 3; pp. 301 - 303
Main Authors D’Amico, Adele, Catteruccia, Michela, De Benedetti, Fabrizio, Vivarelli, Marina, Colucci, Manuela, Cascioli, Simona, Bertini, Enrico
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.05.2012
Subjects
Age of Onset
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Child
Children
CIPD
Demyelination
Electrophysiology
Female
Humans
Immunologic Factors - therapeutic use
Immunosuppressive agents
Inflammation
Neurology
Pediatrics
Polineuropathy
Polyneuropathy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - drug therapy
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating - physiopathology
Rituximab
Young Adult
Rituximab
CIPD
Polineuropathy
Online AccessGet full text

Cover

More Information
Summary:Abstract Childhood-onset chronic inflammatory demyelinating polyneuropathy (CIDP) are generally responsive to conventional immunosuppressant treatments. However about 20% of patients may be refractory to several treatments and the disease has poor outcome. Rituximab is becoming a promising treatment in selected adult cases of severe CIDPs. We report the effectiveness of Rituximab in a refractory childhood-onset CIDP and we suggest this treatment as an effective choice in unresponsive childhood CIDP.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ObjectType-Article-2
ObjectType-Feature-1
ISSN:1090-3798
1532-2130
DOI:10.1016/j.ejpn.2011.08.002